Skip to main content

Table 2 Demographic data of analyzed 244 patients who underwent cisplatin-based chemotherapies

From: A comparison of nephrotoxicity between patients with a solitary-functioning kidney and those with bilateral-functioning kidneys in cisplatin-based chemotherapy for advanced urothelial carcinoma: a Japanese retrospective multi-institutional study

 

All patients

Pretreatment eGFR

≥60 mL/min/1.73m2

Pretreatment eGFR

< 60 mL/min/1.73m2

Pretreatment

eGFR ≥60

mL/min/1.73m2

(n = 119)

Pretreatment

eGFR < 60

mL/min/1.73m2

(n = 125)

p

Bilateral

functioning

kidneys

(n = 83)

Solitary

functioning

kidney

(n = 36)

p

Bilateral

functioning

kidneys

(n = 45)

Solitary

functioning

kidney

(n = 80)

p

Age

< 70

78 (65.5%)

63 (50.4%)

0.016

49 (58.9%)

29 (80.5%)

0.039

20 (44.4%)

43 (53.7%)

0.32

≥70

41 (34.4%)

62 (49.6%)

 

34 (41.1%)

7 (19.5%)

 

25 (55.6%)

37 (46.3%)

 

PS

0-1

111 (93.2%)

117 (93.6%)

0.91

77 (92.7%)

34 (94.4%)

0.94

42 (93.3%)

75 (93.8%)

0.083

2-4

8 (6.7%)

8 (6.4%)

 

6 (7.3%)

2 (5.6%)

 

3 (6.7%)

5 (6.2%)

 

Sex

Male

86 (72.3%)

87 (69.6%)

0.64

61 (73.5%)

25 (69.4%)

0.65

32 (71.1%)

55 (68.7%)

0.78

Female

33 (27.7%)

38 (30.4%)

 

22 (26.5%)

11 (30.6%)

 

13 (28.9%)

25 (31.3%)

 

Comorbidities

yes

15 (12.6%)

17 (14.2%)

0.81

13 (15.7%)

2 (5.6%)

0.12

8 (17.8%)

9 (11.2%)

0.36

no / unknown

104 (87.4%)

108 (86.4%)

 

70 (84.3%)

34 (94.4%)

 

37 (82.2%)

71 (88.8%)

 

DM

3 (2.5%)

4 (3.2%)

 

2 (2.4%)

1 (2.7%)

 

2 (4.4%)

2 (2.4%)

 

Glomerulonephritis

1 (0.8%)

1 (0.8%)

 

1 (1.2%)

0 (0.0%)

 

0 (0.0%)

1 (1.2%)

 

Others

11 (9.2%)

12 (9.6%)

 

10 (12.1%)

1 (2.7%)

 

6 (13.3%)

6 (7.5%)

 

Cancer location

BC

79 (66.5%)

46 (36.8%)

< 0.001

67 (80.7%)

12 (33.3%)

< 0.001

32 (71.1%)

14 (17.5%)

< 0.001

UTUC

32 (26.8%)

74 (59.2%)

 

13 (15.7%)

19 (52.8%)

 

12 (26.7%)

62 (77.5%)

 

BC + UTUC

8 (6.7%)

5 (4.0%)

 

3 (3.6%)

5 (13.9%)

 

1 (2.2%)

4 (5.0%)

 

Surgery

No surgery

85 (71.5%)

73 (58.4%)

0.033

63 (75.9%)

22 (61.1%)

< 0.001

38 (84.4%)

35 (43.7%)

< 0.001

Cystectomy

25 (21.0%)

14 (11.2%)

 

20 (24.1%)

5 (13.9%)

 

7 (15.6%)

7 (8.8%)

 

Nephroureterectomy

7 (5.8%)

37 (29.6%)

 

0 (0.0%)

7 (19.4%)

 

0 (0.0%)

37 (46.3%)

 

Cystectomy + nephroureterectomy

2 (1.7%)

1 (0.8%)

 

0 (0.0%)

2 (5.6%)

 

0 (0.0%)

1 (1.2%)

 

Metastatic site

Lymph node

77 (64.7%)

68 (54.4%)

0.10

55 (66.2%)

22 (61.1%)

0.58

33 (73.3%)

35 (43.8%)

0.001

Lung

41 (34.5%)

45 (36.0%)

0.80

23 (12.1%)

18 (50.0%)

0.018

16 (35.6%)

29 (36.3%)

0.94

Liver

24 (20.2%)

18 (14.4%)

0.23

12 (14.5%)

12 (33.3%)

0.018

6 (13.3%)

12 (15.0%)

0.79

Bone

22 (18.5%)

17 (13.6%)

0.29

13 (15.7%)

9 (25.0%)

0.23

6 (13.3%)

11 (13.7%)

0.95

Others

28 (23.5%)

32 (25.6%)

0.70

15 (18.1%)

13 (36.1%)

0.033

9 (20.0%)

23 (28.7%)

0.28

  1. BC bladder cancer, UTUC upper urinary tract urothelial cancer
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us